Antithrombotic effect of an anti-glycoprotein IIB/IIIA antibody in primate lethal thrombosis.
We investigated the antithrombotic effect of anti-glycoprotein (GP) IIb/IIIa antibody in a primate model of lethal thrombosis. Eight monkeys were injected intravenously with an anti-CD9 antibody (MALL13). They died within 5 min and displayed severe thrombocytopenia. Histological examination showed multiple platelet thrombi in the pulmonary microvasculature, but no thrombi in the liver, kidneys, or spleen. In contrast, monkeys pretreated with an anti-GPIIb/IIIa antibody (NNKY1-32) at 30 min before MALL13 administration did not die, and the thrombocytopenia in these animals did not develop as rapidly or become as severe. These results suggest that the antiCD9 antibody caused lethal pulmonary thrombosis in vivo, and that pretreatment with the anti-GPIIb/IIIa antibody was able to prevent this thrombosis.
Kawakatsu
T
T
First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Suzuki
M
M
Kido
H
H
Sakane
H
H
Hada
S
S
Yamaguchi
K
K
Fukuroi
T
T
Yanabu
M
M
Nagata
H
H
Nomura
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity; D015703:Antigens, CD / Q000276:immunology; D016824:Antigens, Human Platelet / Q000276:immunology*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008251:Macaca; D008562:Membrane Glycoproteins; D051379:Mice; D010974:Platelet Aggregation; D010980:Platelet Membrane Glycoproteins / Q000276:immunology*; D011652:Pulmonary Circulation; D060245:Tetraspanin 29; D013921:Thrombocytopenia / Q000209:etiology; D013927:Thrombosis / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D016824:Antigens, Human Platelet; C554869:CD9 protein, human; C554870:Cd9 protein, mouse; D005343:Fibrinolytic Agents; D008562:Membrane Glycoproteins; D010980:Platelet Membrane Glycoproteins; D060245:Tetraspanin 29; D007770:L-Lactate Dehydrogenase